PharmaEssentia Corporation: Business Overview, Financials & Competitive Analysis
PharmaEssentia Corporation scores 7/10 on the AskCyborg Cyborg Score (Strong). Taiwan-based biotech with validated flagship product (BESREMi®) in high-value orphan disease market, expanding pipeline, and integrated manufacturing platform positions it for sustained growth. With a market cap of approximately 242 billion TWD and PE ratio of 55.86, the company commands investor confidence in a specialized hematology/oncology space. Clinical validation through.
What is PharmaEssentia Corporation's industry? PharmaEssentia Corporation (pharmaessentia.com) operates in Biopharmaceutical Manufacturing & Development. AskCyborg classifies PharmaEssentia Corporation under Biopharmaceutical Manufacturing & Development in its company registry.
PharmaEssentia is a global biopharmaceutical company developing best-in-class therapies for blood disorders and other serious diseases worldwide. Its lead product is Ropeginterferon alfa-2b (BESREMi®) for myeloprolife...
Cyborg Score thesis
Taiwan-based biotech with validated flagship product (BESREMi®) in high-value orphan disease market, expanding pipeline, and...
Read the full analyst-debate transcript →Get the Latest PharmaEssentia Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreePharmaEssentia Corporation Overview
Pro stress-test →PharmaEssentia is a global biopharmaceutical company developing best-in-class therapies for blood disorders and other serious diseases worldwide. Its lead product is Ropeginterferon alfa-2b (BESREMi®) for myeloproliferative neoplasms treatment, alongside pipeline candidates in T-cell receptor therapy, anti-PD-1 immunotherapies, and other novel biologics for solid tumors and hepatocellular carcinoma.
Strategic Profile
Pro stress-test →A fully integrated global biopharmaceutical company based in Taiwan that is competent in R&D, manufacturing, selling and marketing new drugs in the US. The company operates a world-class cGMP biologics facility in Taichung certified by the Taiwan FDA and compliant with US FDA and EMA requirements.
Competitive Landscape
Pro stress-test →PharmaEssentia competes in the myeloproliferative neoplasms treatment space with its differentiated Ropeginterferon alfa-2b product. Direct competitors in the orphan blood disorder and oncology immunotherapy markets include established pharma companies with interferon and checkpoint inhibitor portfolios, though PharmaEssentia's long-acting mono-pegylated formulation offers differentiation in dosing convenience.
Industry Context
PharmaEssentia Corporation operates in Biopharmaceutical Manufacturing & Development.
Key facts
Founded: 1990 · Headquarters: Taipei, Taiwan · Employees: 131 · Market cap: 242.3B TWD